BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Woolley RJ, Ceelen D, Ouwerkerk W, Tromp J, Figarska SM, Anker SD, Dickstein K, Filippatos G, Zannad F, Marco M, Ng L, Samani N, van Veldhuisen DJ, Lang C, Lam CS, Voors AA. Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. Eur J Heart Fail 2021;23:983-91. [PMID: 33651430 DOI: 10.1002/ejhf.2144] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 van Bergeijk KH, Voors AA, Wykrzykowska JJ. Prime time for machine learning to predict clinical outcomes in valvular heart disease? Eur J Heart Fail 2021;23:2033-4. [PMID: 34761488 DOI: 10.1002/ejhf.2379] [Reference Citation Analysis]
2 Liang LW, Raita Y, Hasegawa K, Fifer MA, Maurer MS, Reilly MP, Shimada YJ. Proteomics profiling reveals a distinct high-risk molecular subtype of hypertrophic cardiomyopathy. Heart 2022:heartjnl-2021-320729. [PMID: 35351822 DOI: 10.1136/heartjnl-2021-320729] [Reference Citation Analysis]
3 Stavrakis S, Elkholey K, Morris L, Niewiadomska M, Asad ZUA, Humphrey MB. Neuromodulation of Inflammation to Treat Heart Failure With Preserved Ejection Fraction: A Pilot Randomized Clinical Trial. J Am Heart Assoc 2022;:e023582. [PMID: 35023349 DOI: 10.1161/JAHA.121.023582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Alkhodari M, Jelinek HF, Karlas A, Soulaidopoulos S, Arsenos P, Doundoulakis I, Gatzoulis KA, Tsioufis K, Hadjileontiadis LJ, Khandoker AH. Deep Learning Predicts Heart Failure With Preserved, Mid-Range, and Reduced Left Ventricular Ejection Fraction From Patient Clinical Profiles. Front Cardiovasc Med 2021;8:755968. [PMID: 34881307 DOI: 10.3389/fcvm.2021.755968] [Reference Citation Analysis]
5 Bauersachs J, de Boer RA, Lindenfeld J, Bozkurt B. The year in cardiovascular medicine 2021: heart failure and cardiomyopathies. Eur Heart J 2022:ehab887. [PMID: 34974611 DOI: 10.1093/eurheartj/ehab887] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Tomasoni D, Adamo M, Metra M. April 2022 at a glance: focus on prevention, acute heart failure and heart failure with preserved ejection fraction. Eur J Heart Fail 2022;24:593-5. [PMID: 35545950 DOI: 10.1002/ejhf.2228] [Reference Citation Analysis]
7 Teramoto K, Teng TK, Chandramouli C, Tromp J, Sakata Y, Lam CS. Epidemiology and Clinical Features of Heart Failure with Preserved Ejection Fraction. Card Fail Rev 2022;8:e27. [DOI: 10.15420/cfr.2022.06] [Reference Citation Analysis]
8 Sotomi Y, Hikoso S, Komukai S, Sato T, Oeun B, Kitamura T, Nakagawa A, Nakatani D, Mizuno H, Okada K, Dohi T, Sunaga A, Kida H, Seo M, Yano M, Hayashi T, Nakagawa Y, Tamaki S, Ohtani T, Yasumura Y, Yamada T, Sakata Y; OCVC-Heart Failure Investigator. Phenotyping of acute decompensated heart failure with preserved ejection fraction. Heart 2022:heartjnl-2021-320270. [PMID: 34987067 DOI: 10.1136/heartjnl-2021-320270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Herman R, Vanderheyden M, Vavrik B, Beles M, Palus T, Nelis O, Goethals M, Verstreken S, Dierckx R, Penicka M, Heggermont W, Bartunek J. Utilizing longitudinal data in assessing all-cause mortality in patients hospitalized with heart failure. ESC Heart Fail 2022. [PMID: 35695324 DOI: 10.1002/ehf2.14011] [Reference Citation Analysis]
10 van Ham WB, Kessler EL, Oerlemans MI, Handoko ML, Sluijter JP, van Veen TA, den Ruijter HM, de Jager SC. Clinical Phenotypes of Heart Failure With Preserved Ejection Fraction to Select Preclinical Animal Models. JACC: Basic to Translational Science 2022. [DOI: 10.1016/j.jacbts.2021.12.009] [Reference Citation Analysis]
11 Tomasoni D, Adamo M, Metra M. February 2022 at a glance: focus on pathophysiology and acute heart failure. Eur J Heart Fail 2022;24:243-4. [PMID: 35199407 DOI: 10.1002/ejhf.2224] [Reference Citation Analysis]
12 Abboud A, Nguonly A, Bean A, Brown KJ, Chen RF, Dudzinski D, Fiseha N, Joice M, Kimaiyo D, Martin M, Taylor C, Wei K, Welch M, Zlotoff DA, Januzzi JL, Gaggin HK. Rationale and design of the preserved versus reduced ejection fraction biomarker registry and precision medicine database for ambulatory patients with heart failure (PREFER-HF) study. Open Heart 2021;8:e001704. [PMID: 34663746 DOI: 10.1136/openhrt-2021-001704] [Reference Citation Analysis]
13 Lim GB. AI identifies distinct subgroups of HFpEF. Nat Rev Cardiol 2021;18:387. [PMID: 33742183 DOI: 10.1038/s41569-021-00545-0] [Reference Citation Analysis]
14 Gao Y, Bai X, Lu J, Zhang L, Yan X, Huang X, Dai H, Wang Y, Hou L, Wang S, Tian A, Li J. Prognostic Value of Multiple Circulating Biomarkers for 2-Year Death in Acute Heart Failure With Preserved Ejection Fraction. Front Cardiovasc Med 2021;8:779282. [PMID: 34957261 DOI: 10.3389/fcvm.2021.779282] [Reference Citation Analysis]
15 Bayes-genis A, Cediel G, Domingo M, Codina P, Santiago E, Lupón J. Biomarkers in Heart Failure with Preserved Ejection Fraction. Card Fail Rev 2022;8:e20. [DOI: 10.15420/cfr.2021.37] [Reference Citation Analysis]
16 Vergallo R, Volpe M. Deciphering a decision support tool (CoDE-HF) to improve the diagnosis of acute heart failure. Eur Heart J 2022:ehac372. [PMID: 35866305 DOI: 10.1093/eurheartj/ehac372] [Reference Citation Analysis]
17 Segar MW, Pandey A. Omics, machine learning, and personalized medicine in heart failure with preserved ejection fraction: promising future or false hope? Eur J Heart Fail 2021;23:992-4. [PMID: 34021682 DOI: 10.1002/ejhf.2246] [Reference Citation Analysis]
18 Dong Q, Zhang J, Han Q, Zhang H, Wang M, Huang Q, Zhao J. Global status and trends in heart failure with preserved ejection fraction over the period 2009-2020: A bibliometric analysis. Medicine (Baltimore) 2022;101:e29106. [PMID: 35356948 DOI: 10.1097/MD.0000000000029106] [Reference Citation Analysis]
19 Liang B, Liang Y, Gu N. Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction. BMC Cardiovasc Disord 2022;22:261. [PMID: 35689186 DOI: 10.1186/s12872-022-02693-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 van de Wouw J, Steenhorst JJ, Sorop O, van Drie RWA, Wielopolski PA, Kleinjan A, Hirsch A, Duncker DJ, Merkus D. Impaired pulmonary vasomotor control in exercising swine with multiple comorbidities. Basic Res Cardiol 2021;116:51. [PMID: 34510273 DOI: 10.1007/s00395-021-00891-7] [Reference Citation Analysis]
21 Averbuch T, Sullivan K, Sauer A, Mamas MA, Voors AA, Gale CP, Metra M, Ravindra N, Van Spall HGC. Applications of artificial intelligence and machine learning in heart failure. European Heart Journal - Digital Health 2022;3:311-22. [DOI: 10.1093/ehjdh/ztac025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Huang L, Liang L, Tian P, Zhao L, Chen Y, Huang Y, Zhou Q, Zhai M, Zhang Y, Ambrosio G, Zhang J. D-dimer and outcomes in hospitalized heart failure patients across the ejection fraction phenotypes. ESC Heart Fail 2022. [PMID: 35747927 DOI: 10.1002/ehf2.14049] [Reference Citation Analysis]
23 Linde C, Ekström M, Eriksson MJ, Maret E, Wallén H, Lyngå P, Wedén U, Cabrera C, Löfström U, Stenudd J, Lund LH, Persson B, Persson H, Hage C; for the Stockholm County/Karolinska Institutet 4D heart failure investigators. Baseline characteristics of 547 new onset heart failure patients in the PREFERS heart failure study. ESC Heart Failure. [DOI: 10.1002/ehf2.13922] [Reference Citation Analysis]
24 Aronow WS, Lloji A, Sreenivasan J, Novograd J, Pan S, Lanier GM. Heart failure with preserved ejection fraction: key stumbling blocks for experimental drugs in clinical trials. Expert Opin Investig Drugs 2022. [PMID: 35443138 DOI: 10.1080/13543784.2022.2069009] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]